1CellBio to provide early access to new targeted cell sequencing
Category: #health  | By Mateen Dalal  | Date: 2020-03-31 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

1CellBio to provide early access to new targeted cell sequencing

The U.S.-based biotechnology company, 1CellBio Inc. has recently revealed early access program for its latest droplet-based targeted cell sequencing and selection abilities. Reportedly, this latest approach aligns with the present inDrop™ workflow for a wide-range of pharmaceutical, biological research, and clinical applications.

According to reliable sources, this approach is different from its contemporary methods. In this, a cell-based assay detects and chooses microdroplets possessing rare individual B cells out of an immune repertory, after which the chosen cells are barcoded for targeted sequencing of the V gene and the antibodies are recovered by V gene expression and cloning.

A similar kind of targeted cell sequencing and selection technique was demonstrated in the newly issued Nature Biotechnology article. This platform was the initial peer-reviewed report of deep mining, high-throughput of antibody repertoires to find high-affinity, rare, functional antibodies against compound drug targets in local states.

Speaking on the move, Colin J.H. Brenan, PhD, CEO, 1CellBio, said that in this program, the company’s exclusive inDrop technology was employed to showcase a high-throughput unique approach of screening antibody repertoires.

1CellBio’s new, early access study sheds light on new co-development partnerships that could help boost a myriad of applications such as antibody discovery, tumor profiling, rare cell isolation and sequencing, T cell receptor profiling, novel materials discovery, single-cell sequencing and screening of complex libraries and cytotoxic assays.

In other news, nference, a clinical data analytics platform, recently launched a software application that synthesizes disparate scRNA-seq (Single Cell RNA-sequencing) data sets to help researchers fight against the COVID-19 pandemic.

Reportedly, the resource comes with the augmented intelligence technology of nferX that prepares machines to comprehend more than 100 million unstructured biomedical data and coordinate these insights accordingly.

Venky Soundararajan, Ph.D., Chief Scientific Officer and Co-Founder, nference, commented that the single-cell technology comes as a strong lens for examining molecules that are associated with COVID-19.

Source Credit: https://apnews.com/Business%20Wire/8aba7823ab9b4183b9f620b9d4770c90

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

ChatGPT’s creator OpenAI proposes regulation of AI by humans

ChatGPT’s creator OpenAI proposes regulation of AI by humans

By Mateen Dalal

OpenAI, the creator of ChatGPT, has reportedly put forward a proposal for the establishment of an international organization to regulate artificial intelligence (AI). Led by CEO Sam Altman, the company believes that AI systems developed within the ne...

Medtronic pledges USD 350 Mn to expand R&D operations in India

Medtronic pledges USD 350 Mn to expand R&D operations in India

By Mateen Dalal

Medtronic, a leading healthcare technology company, has announced plans to expand its R&D center in Hyderabad, India, with a whopping investment of USD 350 million. The existing facility is already the largest center for the company outside the U...

DuPont to buy Spectrum Plastics, anticipates high ROIC by fifth year

DuPont to buy Spectrum Plastics, anticipates high ROIC by fifth year

By Mateen Dalal

American chemical company DuPont de Nemours Inc. reportedly signed a definitive agreement to buy out Spectrum Plastics Group from AEA Investors, a U.S. based private equity firm. The acquisition will reinforce DuPont’s position in booming non-c...